Singapore has officially approved the Arexvy vaccine that provides protection against the respiratory syncytial virus (RSV) for adults aged 60 and older. This important development, granted by the Health Sciences Authority (HSA) on May 10, addresses a critical need for vaccination against a virus known to cause serious respiratory infections that could lead to complications in older adults.
Login to read more
